NSTGQ vs. FRTX, CELZ, PALI, TCON, TTNP, FNCH, KRBP, ALBT, SRNE, and ELOX
Should you be buying NanoString Technologies stock or one of its competitors? The main competitors of NanoString Technologies include Fresh Tracks Therapeutics (FRTX), Creative Medical Technology (CELZ), Palisade Bio (PALI), TRACON Pharmaceuticals (TCON), Titan Pharmaceuticals (TTNP), Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), Avalon GloboCare (ALBT), Sorrento Therapeutics (SRNE), and Eloxx Pharmaceuticals (ELOX). These companies are all part of the "biological products, except diagnostic" industry.
Fresh Tracks Therapeutics (NASDAQ:FRTX) and NanoString Technologies (NASDAQ:NSTGQ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
Fresh Tracks Therapeutics has higher earnings, but lower revenue than NanoString Technologies. Fresh Tracks Therapeutics is trading at a lower price-to-earnings ratio than NanoString Technologies, indicating that it is currently the more affordable of the two stocks.
Fresh Tracks Therapeutics and NanoString Technologies both received 0 outperform votes by MarketBeat users.
Fresh Tracks Therapeutics has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, NanoString Technologies has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500.
Fresh Tracks Therapeutics has a net margin of -91.29% compared to Fresh Tracks Therapeutics' net margin of -102.44%. Fresh Tracks Therapeutics' return on equity of 0.00% beat NanoString Technologies' return on equity.
In the previous week, NanoString Technologies' average media sentiment score of 0.00 equaled Fresh Tracks Therapeutics'average media sentiment score.
25.0% of Fresh Tracks Therapeutics shares are held by institutional investors. Comparatively, 76.8% of NanoString Technologies shares are held by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are held by company insiders. Comparatively, 3.1% of NanoString Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Fresh Tracks Therapeutics beats NanoString Technologies on 6 of the 11 factors compared between the two stocks.
Get NanoString Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NSTGQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NSTGQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NSTGQ vs. The Competition
NanoString Technologies Competitors List
Related Companies and Tools
